Table 1

Baseline characteristics of 795 individuals with COPD

Statins
N=253
No statins
N=542
p Value
Mean age at enrolment in years (SD)68.2 (8.4)67.6 (10.5)0.391
Male (number (%))169 (66.8)317 (58.5)0.025
Current smoker (number (%))59 (23.3)153 (28.2)0.145
Mean BMI at enrolment (SD)28.5 (5.7)26.5 (5.2)0.000
GOLD stage (number (%))0.024
 I28 (11.1)42 (7.8)
 II114 (45.2)209 (38.8)
 III93 (36.9)223 (41.4)
 IV17 (6.7)65 (12.1)
Lung function
 Mean FEV1 in litres (SD)1.5 (0.6)1.4 (0.6)0.007
 Mean FEV1% predicted (SD)54.6 (18.7)50.9 (19.6)0.012
 Mean FEV1/VC % predicted (SD)46.9 (13.7)43.4 (13.4)0.001
Comorbidities (number (%))
 Congestive heart failure63 (24.9)76 (14.0)0.000
 Myocardial infarction272 (8.7)8 (1.5)0.000
 Hypertension19 (7.5)21 (3,9)0.029
 Diabetes mellitus37 (14.6)15 (2.8)0.000
 Mean mMRC score (SD)1.8 (1.2)1.7 (1.3)0.500
 Mean ADO score (SD)4.2 (1.6)4.1 (2.0)0.745
 Mean BOD score (SD)2.3 (1.6)2.5 (1.8)0.061
 Median pack-years35.435.00.920
  • AECOPD, acute exacerbation of COPD; COPD, chronic obstructive pulmonary disease; FEV, forced expiratory volume; mMRC, modified Medical Research Council Dyspnea Questionnaire; VC, vital capacity.